Insider Transactions in Q1 2024 at Gemini Therapeutics, Inc. (GMTX)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 05
2024
|
Kevin Bitterman |
SELL
Open market or private sale
|
Indirect |
26,157
-3.72%
|
$1,909,461
$73.5 P/Share
|
|
Feb 26
2024
|
Pamela Stephenson Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
36,666
+50.0%
|
-
|
|
Feb 07
2024
|
Jean M. Franchi Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
36,666
+50.0%
|
-
|
|
Jan 23
2024
|
Atlas Venture Fund X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
102,500
-9.83%
|
$6,867,500
$67.65 P/Share
|
|
Jan 23
2024
|
Atlas Venture Fund X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
47,500
-3.28%
|
$3,182,500
$67.65 P/Share
|
|
Jan 23
2024
|
Kevin Bitterman |
SELL
Open market or private sale
|
Indirect |
102,500
-9.83%
|
$6,867,500
$67.65 P/Share
|
|
Jan 10
2024
|
Joanne Bryce Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,165
+43.43%
|
-
|
|
Jan 10
2024
|
John D Quisel Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
66,365
+49.0%
|
-
|
|
Jan 10
2024
|
William Jacob Savage Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,535
+46.26%
|
-
|
|
Jan 10
2024
|
Jonathan Yen Wen Yu Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,165
+50.0%
|
-
|
|
Jan 10
2024
|
Rahul Khara General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
14,035
+50.0%
|
-
|
|
Jan 10
2024
|
Atlas Venture Fund X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
20,000
-2.48%
|
$1,280,000
$64.0 P/Share
|
|
Jan 10
2024
|
Atlas Venture Fund X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
30,000
-2.03%
|
$1,920,000
$64.0 P/Share
|
|
Jan 10
2024
|
Kevin Bitterman |
SELL
Open market or private sale
|
Indirect |
20,000
-2.48%
|
$1,280,000
$64.0 P/Share
|